Maze Therapeutics (NASDAQ:MAZE) CEO Sells 34,501 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares in the company, valued at $477,189.79. This represents a 65.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Down 3.2%

Maze Therapeutics stock traded down $0.85 during trading on Thursday, reaching $25.87. The company had a trading volume of 477,427 shares, compared to its average volume of 639,798. Maze Therapeutics, Inc. has a 12-month low of $14.16 and a 12-month high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock’s 50 day moving average price is $28.76 and its two-hundred day moving average price is $31.34. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -10.27 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MAZE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Trading of Maze Therapeutics

Several large investors have recently added to or reduced their stakes in MAZE. Royal Bank of Canada boosted its position in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its position in Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after acquiring an additional 931 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after acquiring an additional 977 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.